Italia markets closed

Aptose Biosciences Inc. (APS.TO)

Toronto - Toronto Prezzo in tempo reale. Valuta in CAD.
Aggiungi a watchlist
1,6800-0,0100 (-0,59%)
Alla chiusura: 01:16PM EDT
Schermo intero
Chiusura precedente1,6900
Aperto1,7300
Denaro1,6900 x N/D
Lettera1,7100 x N/D
Min-Max giorno1,6800 - 1,7300
Intervallo di 52 settimane1,5900 - 10,3500
Volume200
Media Volume9.282
Capitalizzazione27,304M
Beta (5 anni mensile)1,47
Rapporto PE (ttm)N/D
EPS (ttm)-10,4100
Prossima data utili14 mag 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1A31,02
  • GlobeNewswire

    Aptose Clinical and Preclinical Data to be Presented at European School of Haematology (ESH) 6th International Conference

    Company to Hold Clinical Update Webcast; Details ForthcomingSAN DIEGO and TORONTO, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that two abstracts on tuspetinib, Aptose’s Phase 1/2 myeloid kinase inhibitor in development for acute myeloid leukemia (AML), have been accepted for post

  • GlobeNewswire

    Aptose to Present at the Cantor Global Healthcare Conference

    SAN DIEGO and TORONTO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that the Aptose management team will participate in the Cantor Global Healthcare Conference being held September 26-28, 2023, in New York City. Dr. William G. Rice, Chairman, President and CEO of Aptose, will part

  • GlobeNewswire

    Aptose Announces Closing of $3 Million Investment by Hanmi Pharmaceutical

    — TUS/VEN doublet continues safe and effective in AML patients who failed prior venetoclax —SAN DIEGO and TORONTO, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced closing of a $3 million investment in common shares of the Company (the “Shares”) as the first tranche of a private equity